Data from the Hong Kong Stock Exchange shows that on July 30, a significant position change occurred in INNOGEN-B (02591), with depositary shares valued at a total of HK$188 million, representing a 6.03% stake. A company shareholder deposited 25.2905 million shares into Citibank, increasing their shareholding ratio by 6.02%.

The company's financial results for the year ended December 31, 2025, indicate that the group generated approximately RMB 131.5 million in revenue, primarily from the sale of Yisupaglutide Alpha in China. The net loss stood at RMB 341 million, expanding by 95.4% year-over-year, with a basic loss per share of RMB 0.79.